Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prusogliptin plus Metformin in Type 2 Diabetes
NCT04218734Phase 3Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of prusogliptin in type 2 diabetes mellitus (T2DM), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jan 2020; status: completed.
02
Drugs
prusogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04218734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04218734.